The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance.
Aleksander M BogdanskiAnke M OnnekinkAkin IndersonBas BoekestijnBert A BonsingHans F A VasenJeanin E van HooftJurjen J BoonstraJ Sven D MieogMartin N J M WasserShirin FeshtaliThomas P PotjerDerk C F KlatteMonique E van LeerdamPublished in: Pancreas (2024)
In this study, we found no added value for longitudinal glucose monitoring in CDKN2A pathogenic variant carriers participating in an imaging-based pancreatic cancer surveillance program.